GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Cyclically Adjusted Price-to-FCF

Biogen (BSP:BIIB34) Cyclically Adjusted Price-to-FCF : 11.24 (As of Jun. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Biogen Cyclically Adjusted Price-to-FCF?

As of today (2024-06-25), Biogen's current share price is R$204.20. Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was R$18.17. Biogen's Cyclically Adjusted Price-to-FCF for today is 11.24.

The historical rank and industry rank for Biogen's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BSP:BIIB34' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 8.91   Med: 32.04   Max: 107.99
Current: 10.27

During the past years, Biogen's highest Cyclically Adjusted Price-to-FCF was 107.99. The lowest was 8.91. And the median was 32.04.

BSP:BIIB34's Cyclically Adjusted Price-to-FCF is ranked better than
88.2% of 322 companies
in the Drug Manufacturers industry
Industry Median: 30.22 vs BSP:BIIB34: 10.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogen's adjusted free cash flow per share data for the three months ended in Mar. 2024 was R$2.449. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is R$18.17 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biogen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Price-to-FCF Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.82 15.94 13.36 14.55 12.23

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.23 13.25 11.84 12.23 9.89

Competitive Comparison of Biogen's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted Price-to-FCF falls into.



Biogen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biogen's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=204.20/18.17
=11.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biogen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.449/131.7762*131.7762
=2.449

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 1.449 100.560 1.899
201409 1.394 100.428 1.829
201412 1.480 99.070 1.969
201503 1.406 99.621 1.860
201506 2.011 100.684 2.632
201509 1.838 100.392 2.413
201512 3.061 99.792 4.042
201603 2.408 100.470 3.158
201606 2.305 101.688 2.987
201609 1.749 101.861 2.263
201612 3.588 101.863 4.642
201703 -1.996 102.862 -2.557
201706 2.182 103.349 2.782
201709 3.312 104.136 4.191
201712 3.153 104.011 3.995
201803 3.220 105.290 4.030
201806 2.520 106.317 3.123
201809 5.220 106.507 6.458
201812 5.376 105.998 6.683
201903 4.312 107.251 5.298
201906 5.974 108.070 7.284
201909 5.958 108.329 7.248
201912 6.484 108.420 7.881
202003 5.649 108.902 6.836
202006 9.868 108.767 11.956
202009 6.255 109.815 7.506
202012 -2.594 109.897 -3.110
202103 4.154 111.754 4.898
202106 6.425 114.631 7.386
202109 4.384 115.734 4.992
202112 4.899 117.630 5.488
202203 0.582 121.301 0.632
202206 3.999 125.017 4.215
202209 3.618 125.227 3.807
202212 -1.571 125.222 -1.653
202303 2.285 127.348 2.364
202306 2.215 128.729 2.267
202309 2.858 129.860 2.900
202312 -0.294 129.419 -0.299
202403 2.449 131.776 2.449

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (BSP:BIIB34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biogen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BSP:BIIB34) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines